| P50 | author | Belinda Duchêne | Q53225077 |
| | Nicolas Jonckheere | Q53225113 |
| | Isabelle Van Seuningen | Q58158912 |
| | Romain Vasseur | Q87147072 |
| P2093 | author name string | Audrey Vincent | |
| | Nicolas Skrypek | |
| P2860 | cites work | Global cancer statistics | Q22241238 |
| | let-7 MicroRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression | Q28239424 |
| | DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition | Q29400901 |
| | FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer | Q29547638 |
| | Topoisomerase I inhibitors: camptothecins and beyond | Q29614976 |
| | Targeting multidrug resistance in cancer | Q29616803 |
| | ERBB2 overexpression suppresses stress-induced autophagy and renders ERBB2-induced mammary tumorigenesis independent of monoallelic Becn1 loss | Q33878879 |
| | Cancer biomarkers: can we turn recent failures into success? | Q34176379 |
| | The mucin MUC4 and its membrane partner ErbB2 regulate biological properties of human CAPAN-2 pancreatic cancer cells via different signalling pathways | Q34185812 |
| | The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis | Q34493341 |
| | ABC multidrug transporters: structure, function and role in chemoresistance. | Q34586418 |
| | Pancreatic adenocarcinoma: new strategies for success | Q37198628 |
| | Cancer biomarkers: are we ready for the prime time? | Q37307199 |
| | Tumour growth and resistance to gemcitabine of pancreatic cancer cells are decreased by AP-2alpha overexpression. | Q37330687 |
| | Pharmacogenetic pathway analysis of irinotecan | Q37381224 |
| | Signal integration by JNK and p38 MAPK pathways in cancer development | Q37560607 |
| | The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family. | Q37605606 |
| | Sequence of the 5'-flanking region and promoter activity of the human mucin gene MUC5B in different phenotypes of colon cancer cells | Q38311644 |
| | Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine | Q38948274 |
| | p53 status determines the role of autophagy in pancreatic tumour development | Q39048945 |
| | Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States | Q39190004 |
| | Autophagy induced by p53-reactivating molecules protects pancreatic cancer cells from apoptosis. | Q39226379 |
| | Trastuzumab has opposing effects on SN-38-induced double-strand breaks and cytotoxicity in HER2-positive gastric cancer cells depending on administration sequence. | Q39610962 |
| | Role of efflux pump activity in lapatinib/caelyx combination in breast cancer cell lines | Q39799826 |
| | The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38. | Q39836423 |
| | Suppression of ErbB-2 in androgen-independent human prostate cancer cells enhances cytotoxic effect by gemcitabine in an androgen-reduced environment | Q39847370 |
| | AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl | Q40093939 |
| | Regulation of the human mucin MUC4 by taurodeoxycholic and taurochenodeoxycholic bile acids in oesophageal cancer cells is mediated by hepatocyte nuclear factor 1alpha. | Q40220702 |
| | Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma. | Q40464000 |
| | The murine Muc2 mucin gene is transcriptionally regulated by the zinc-finger GATA-4 transcription factor in intestinal cells | Q40492838 |
| | ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan-treated metastases. | Q40577436 |
| | Expression of multidrug resistance-associated protein 2 in human gallbladder carcinoma | Q41444935 |
| | Cell apoptosis: requirement of H2AX in DNA ladder formation, but not for the activation of caspase-3. | Q41927415 |
| | Sorafenib overcomes irinotecan resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux pump. | Q45736203 |
| | HER2 overexpression correlates with survival after curative resection of pancreatic cancer. | Q46016285 |
| | Differences in transcript levels of ABC transporters between pancreatic adenocarcinoma and nonneoplastic tissues. | Q46476988 |
| | A role for human MUC4 mucin gene, the ErbB2 ligand, as a target of TGF-beta in pancreatic carcinogenesis. | Q47376029 |
| | Constitutive Expression of MAP Kinase Phosphatase-1 Confers Multi-drug Resistance in Human Glioblastoma Cells. | Q48325028 |
| | Of autophagy and in vivo pancreatic carcinogenesis: the p53 status matters! | Q53235695 |
| | Pancreatic Cancer | Q54135367 |
| | Copy number of chromosome 17 but not HER2 amplification predicts clinical outcome of patients with pancreatic ductal adenocarcinoma | Q81073375 |
| | Breast cancer resistance protein expression is associated with early recurrence and decreased survival in resectable pancreatic cancer patients | Q83502693 |
| | ABCC2 (MRP2, cMOAT) localized in the nuclear envelope of breast carcinoma cells correlates with poor clinical outcome | Q85071186 |
| P4510 | describes a project that uses | ImageQuant | Q112270642 |
| P433 | issue | 13 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multiple drug resistance | Q643839 |
| | pancreatic cancer | Q212961 |
| P304 | page(s) | 10853-10867 | |
| P577 | publication date | 2015-05-01 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2 | |
| P478 | volume | 6 | |